Novel Bragg peak characterization method using proton flux measurements on plastic scintillators

This work aims to characterize a proton pencil beam scanning (PBS) and passive double scattering (DS) systems as well as to measure parameters relevant to the relative biological effectiveness (RBE) of the beam using a silicon on insulator (SOI) microdosimeter with well-defined 3D sensitive volumes (SV). The dose equivalent downstream and laterally outside of a clinical PBS treatment field was assessed and compared to that of a DS beam. A novel silicon microdosimeter with well-defined 3D SVs was used in this study. It was connected to low noise electronics, allowing for detection of lineal energies as low as 0.15keV/μm. The microdosimeter was placed at various depths in a water phantom along the central axis of the proton beam, and at the distal part of the spread-out Bragg peak (SOBP) in 0.5mm increments. The RBE values of the pristine Bragg peak (BP) and SOBP were derived using the measured microdosimetric lineal energy spectra as inputs to the modified microdosimetric kinetic model (MKM). Geant4 simulations were performed in order to verify the calculated depth-dose distribution from the treatment planning system (TPS) and to compare the simulated dose-mean lineal energy to the experimental results. For a 131MeV PBS spot (124.6mm R90 range in water), the measured dose-mean lineal energy yD¯ increased from 2keV/μm at the entrance to 8keV/μm in the BP, with a maximum value of 10keV/μm at the distal edge. The derived RBE distribution for the PBS beam slowly increased from 0.97±0.14 at the entrance to 1.04±0.09 proximal to the BP, then to 1.1±0.08 in the BP, and steeply rose to 1.57±0.19 at the distal part of the BP. The RBE distribution for the DS SOBP beam was approximately 0.96±0.16 to 1.01±0.16 at shallow depths, and 1.01±0.16 to 1.28±0.17 within the SOBP. The RBE significantly increased from 1.29±0.17 to 1.43±0.18 at the distal edge of the SOBP. The SOI microdosimeter with its well-defined 3D SV has applicability in characterizing proton radiation fields and can measure relevant physical parameters to model the RBE with submillimeter spatial resolution. It has been shown that for a physical dose of 1.82Gy at the BP, the derived RBE based on the MKM model increased from 1.14 to 1.6 in the BP and its distal part. Good agreement was observed between the experimental and simulation results, confirming the potential application of SOI microdosimeter with 3D SV for quality assurance in proton therapy.

PurposeIn this article, we evaluate a plastic scintillation detector system for quality assurance in proton therapy using a BC‐408 plastic scintillator, a commercial camera, and a computer.MethodsThe basic characteristics of the system were assessed in a series of proton irradiations. The reproducibility and response to changes of dose, dose‐rate, and proton energy were determined. Photographs of the scintillation light distributions were acquired, and compared with Geant4 Monte Carlo simulations and with depth‐dose curves measured with an ionization chamber. A quenching effect was observed at the Bragg peak of the 60 MeV proton beam where less light was produced than expected. We developed an approach using Birks equation to correct for this quenching. We simulated the linear energy transfer (LET) as a function of depth in Geant4 and found Birks constant by comparing the calculated LET and measured scintillation light distribution. We then used the derived value of Birks constant to correct the measured scintillation light distribution for quenching using Geant4.ResultsThe corrected light output from the scintillator increased linearly with dose. The system is stable and offers short‐term reproducibility to within 0.80%. No dose rate dependency was observed in this work.ConclusionsThis approach offers an effective way to correct for quenching, and could provide a method for rapid, convenient, routine quality assurance for clinical proton beams. Furthermore, the system has the advantage of providing 2D visualization of individual radiation fields, with potential application for quality assurance of complex, time‐varying fields.

Purpose: To develop a simple algorithm in designing the range modulation wheel to generate a very smooth Spread‐Out Bragg peak (SOBP) for proton therapy.Method and Materials: A simple algorithm has been developed to generate the weight factors in corresponding pristine Bragg peaks which composed a smooth SOBP in proton therapy. We used a modified analytical Bragg peak function based on Monte Carol simulation tool‐kits of Geant4 as pristine Bragg peaks input in our algorithm. A simple METLAB© Quad Program was introduced to optimize the cost function in our algorithm. Results: We found out that the existed analytical function of Bragg peak can't directly use as pristine Bragg peak dose‐depth profile input file in optimization of the weight factors since this model didn't take into account of the scattering factors introducing from the range shifts in modifying the proton beam energies. We have done Geant4 simulations for proton energy of 63.4 MeV with a 1.08 cm SOBP for variation of pristine Bragg peaks which composed this SOBP and modified the existed analytical Bragg peak functions for their peak heights, ranges of R0, and Gaussian energies σE. We found out that 19 pristine Bragg peaks are enough to achieve a flatness of 1.5% of SOBP which is the best flatness in the publications. Conclusion: This work develops a simple algorithm to generate the weight factors which is used to design a range modulation wheel to generate a smooth SOBP in protonradiation therapy. We have found out that a medium number of pristine Bragg peaks are enough to generate a SOBP with flatness less than 2%. It is potential to generate data base to store in the treatment plan to produce a clinic acceptable SOBP by using our simple algorithm.

Purpose: The recommended value for the relative biological effectiveness (RBE) of proton beams is currently assumed to be 1.1. However, there is increasing evidence that RBE increases towards the end of proton beam range that may increase the biological effect of proton beam in the distal regions of the dose deposition. Methods: A computational approach is presented for estimating the biological effect of the proton beam. It includes a method for calculating the dose averaged linear energy transfer (LET) along the measured Bragg peak and published LET to RBE conversion routine. To validate the proposed method, we have performed Monte Carlo simulations of the pristine Bragg peak at various beam energies and compared the analysis with the simulated results. A good agreement within 5% is observed between the LET analysis of the modeled Bragg peaks and Monte Carlo simulations. Results: Applying the method to the set of Bragg peaks measured at a proton therapy facility we have estimated LET and RBE values along each Bragg peak. Combining the individual RBE-weighted Bragg peaks with known energy modulation weights we have calculated the RBE-weighted dose in the modulated proton beam. The proposed computational method provides a tool for calculating dose averaged LET along the measured Bragg peak. Conclusions: Combined with a model to convert LET into RBE, this method enables calculation of RBE-weighted dose both in pristine Bragg peak and in modulated beam in proton therapy.

TOPAS (TOol for PArticle Simulation) is a particle simulation code recently developed with the specific aim of making Monte Carlo simulations user-friendly for research and clinical physicists in the particle therapy community. The authors present a thorough and extensive experimental validation of Monte Carlo simulations performed with TOPAS in a variety of setups relevant for proton therapy applications. The set of validation measurements performed in this work represents an overall end-to-end testing strategy recommended for all clinical centers planning to rely on TOPAS for quality assurance or patient dose calculation and, more generally, for all the institutions using passive-scattering proton therapy systems. The authors systematically compared TOPAS simulations with measurements that are performed routinely within the quality assurance (QA) program in our institution as well as experiments specifically designed for this validation study. First, the authors compared TOPAS simulations with measurements of depth-dose curves for spread-out Bragg peak (SOBP) fields. Second, absolute dosimetry simulations were benchmarked against measured machine output factors (OFs). Third, the authors simulated and measured 2D dose profiles and analyzed the differences in terms of field flatness and symmetry and usable field size. Fourth, the authors designed a simple experiment using a half-beam shifter to assess the effects of multiple Coulomb scattering, beam divergence, and inverse square attenuation on lateral and longitudinal dose profiles measured and simulated in a water phantom. Fifth, TOPAS' capabilities to simulate time dependent beam delivery was benchmarked against dose rate functions (i.e., dose per unit time vs time) measured at different depths inside an SOBP field. Sixth, simulations of the charge deposited by protons fully stopping in two different types of multilayer Faraday cups (MLFCs) were compared with measurements to benchmark the nuclear interaction models used in the simulations. SOBPs' range and modulation width were reproduced, on average, with an accuracy of +1, -2 and ±3 mm, respectively. OF simulations reproduced measured data within ±3%. Simulated 2D dose-profiles show field flatness and average field radius within ±3% of measured profiles. The field symmetry resulted, on average in ±3% agreement with commissioned profiles. TOPAS accuracy in reproducing measured dose profiles downstream the half beam shifter is better than 2%. Dose rate function simulation reproduced the measurements within ∼2% showing that the four-dimensional modeling of the passively modulation system was implement correctly and millimeter accuracy can be achieved in reproducing measured data. For MLFCs simulations, 2% agreement was found between TOPAS and both sets of experimental measurements. The overall results show that TOPAS simulations are within the clinical accepted tolerances for all QA measurements performed at our institution. Our Monte Carlo simulations reproduced accurately the experimental data acquired through all the measurements performed in this study. Thus, TOPAS can reliably be applied to quality assurance for proton therapy and also as an input for commissioning of commercial treatment planning systems. This work also provides the basis for routine clinical dose calculations in patients for all passive scattering proton therapy centers using TOPAS.

BANG®-Polymergeldosimetrie in der Protonentherapie von Augentumoren

Quality assurance (QA) is essential in safe and accurate delivery of radiation therapy. However, QA in proton therapy is challenging due to complicated and often facility-specific beam delivery systems and limited beam time for QA. The purpose of this study is to develop an efficient and comprehensive QA procedure for a multi-room proton therapy center using uniform scanning beams. Our proton therapy center is comprised of a 230 MeV cyclotron, one fixed beam room, two inclined beam rooms, and one gantry room. Uniform scanning is employed exclusively in all treatment rooms. A rfDaily QA3 (Sun Nuclear Inc., Melbourne, Florida) together with home-made devices is used for daily QA. Parallel plane chambers, a multi-layer ionization chamber array (Zebra, IBA dosimetry, Schwarzenbruck, German), and an IC profiler (Sun Nuclear Inc., Melbourne, Florida) are used to QA the characteristics of the uniform scanning beams, including output, range, modulation width, flatness, symmetry, and penumbra, for both monthly and annual QA. QA procedures and acceptance criteria were developed, taking into account the likelihood and potential risk of failure, as well as the available equipment, personnel and other resources. QA procedures and tolerances were developed for daily, monthly and annual QA at our proton therapy center. Daily QA is performed by radiation therapists, and can be completed within 30 minutes for all rooms. Monthly QA and annual QA are performed by physicists, taking about 4 hours and a weekend respectively. Trend analysis was performed for various machine characteristics, such as machine output, range, flatness, and symmetry. QA standards are desired in Radiation Oncology, but not many standards are developed and available for proton therapy. In the mean time, facility-specific QA procedures should be developed based on the equipment failure modes and available resources.

The measurement of depth dose profiles for range and energy verification of heavy ion beams is an important aspect of quality assurance procedures for heavy ion therapy facilities. The steep dose gradients in the Bragg peak region of these profiles require the use of detectors with high spatial resolution. The aim of this work is to characterize a one dimensional monolithic silicon detector array called the "serial Dose Magnifying Glass" (sDMG) as an independent ion beam energy and range verification system used for quality assurance conducted for ion beams used in heavy ion therapy. The sDMG detector consists of two linear arrays of 128 silicon sensitive volumes each with an effective size of 2mm × 50μm × 100μm fabricated on a p-type substrate at a pitch of 200 μm along a single axis of detection. The detector was characterized for beam energy and range verification by measuring the response of the detector when irradiated with a 290 MeV/u 12 C ion broad beam incident along the single axis of the detector embedded in a PMMA phantom. The energy of the 12 C ion beam incident on the detector and the residual energy of an ion beam incident on the phantom was determined from the measured Bragg peak position in the sDMG. Ad hoc Monte Carlo simulations of the experimental setup were also performed to give further insight into the detector response. The relative response profiles along the single axis measured with the sDMG detector were found to have good agreement between experiment and simulation with the position of the Bragg peak determined to fall within 0.2 mm or 1.1% of the range in the detector for the two cases. The energy of the beam incident on the detector was found to vary less than 1% between experiment and simulation. The beam energy incident on the phantom was determined to be (280.9 ± 0.8) MeV/u from the experimental and (280.9 ± 0.2) MeV/u from the simulated profiles. These values coincide with the expected energy of 281 MeV/u. The sDMG detector response was studied experimentally and characterized using a Monte Carlo simulation. The sDMG detector was found to accurately determine the 12 C beam energy and is suited for fast energy and range verification quality assurance. It is proposed that the sDMG is also applicable for verification of treatment planning systems that rely on particle range.

Radiation delivery with ultra-high dose rate (FLASH) radiotherapy (RT) holds promise for improving treatment outcomes and reducing side effects but poses challenges in radiation delivery accuracy due to its ultra-high dose rates. This necessitates the development of novel imaging and verification technologies tailored to these conditions. Our study explores the effectiveness of proton-induced acoustic imaging (PAI) in tracking the Bragg peak in three dimensions and in real time during FLASH proton irradiations, offering a method for volumetric beam imaging at both conventional and FLASH dose rates. We developed a three-dimensional (3D) PAI technique using a 256-element ultrasound detector array for FLASH dose rate proton beams. In the study, we tested protoacoustic signal with a beamline of a FLASH-capable synchrocyclotron, setting the distal 90% of the Bragg peak around 35mm away from the ultrasound array. This configuration allowed us to assess various total proton radiation doses, maintaining a consistent beam output of 21 pC/pulse. We also explored a spectrum of dose rates, from 15 Gy/s up to a FLASH rate of 48 Gy/s, by administering a set number of pulses. Furthermore, we implemented a three-dot scanning beam approach to observe the distinct movements of individual Bragg peaks using PAI. All these procedures utilized a proton beam energy of 180 MeV to achieve the maximum possible dose rate. Our findings indicate a strong linear relationship between protoacoustic signal amplitudes and delivered doses (R2=0.9997), with a consistent fit across different dose rates. The technique successfully provided 3D renderings of Bragg peaks at FLASH rates, validated through absolute Gamma index values. The protoacoustic system demonstrates effectiveness in 3D visualization and tracking of the Bragg peak during FLASH proton therapy, representing a notable advancement in proton therapy quality assurance. This method promises enhancements in protoacoustic image guidance and real-time dosimetry, paving the way for more accurate and effective treatments in ultra-high dose rate therapy environments.

Proton therapy has a distinct dosimetric advantage over conventional photon therapy due to its Bragg peak profile. This allows greater accuracy in dose delivery and dose conformation to the target, however it requires greater precision in setup, delivery and for quality assurance (QA) procedures. The AAPM TG 224 report recommends daily range and spot position checks with tolerance on the order of a millimetre. Daily QA systems must therefore be efficient for daily use and be capable of sub-millimetre precision however few suitable commercial systems are available. In this work, a compact, real-time daily QA system is optimised and characterised for proton range verification using an ad-hoc Geant4 simulation. The system is comprised of a monolithic silicon diode array detector embedded in a perspex phantom. The detector is orientated at an angular offset to the incident proton beam to allow range in perspex to be determined for flat proton fields. The accuracy of the system for proton range in perspex measurements was experimentally evaluated over the full range of clinical proton energies. The mean R 100, R 90 and R 80 ranges measured with the system were accurate within ±0.6 mm of simulated ranges in a perspex phantom for all energies assessed. This system allows real-time read-out of individual detector channels also making it appropriate for temporal beam delivery diagnostics and for spot position monitoring along one axis. The system presented provides a suitable, economical and efficient alternative for daily QA in proton therapy.

We present here a novel method for using a single device in the daily quality assurance (QA) of pencil beam scanning (PBS) proton beams and an improved method for uniform scanning (US). The device can be used to measure the spot position, spot sigma, range, output, collinearity of the X‐ray system and proton beam, and to QA the first scatterers and a number of other imaging and mechanical checks. We have performed the daily QA according to this procedure for more than six months in both a PBS gantry and a US gantry. All of the tests were found to be sensitive and accurate enough to determine if the property being tested is within the tolerance. The output has remained within the ±2% tolerance, with the majority of measurements within ±1%, and the range was within ±0.5mm. The collinearity of the proton beam in both gantries is within the ±1mm tolerance in both X and Y directions for all measurements. A novel procedure to measure the functionality of the first scatterers in the US gantry is included in the QA procedure. It was found to be sensitive enough to pick up the thinnest scatterer of 0.6 mm in both possible failure methods — when it always remains in the beam or in the case when it never goes into the beam. The daily QA procedure presented here can be implemented at PBS or US proton therapy centers with a minimal outlay for equipment and setup time. The procedure can be performed in less than 30 min, and has been found to be accurate and reliable enough for the QA of a proton therapy gantry before patient treatment every day.PACS number: 87.55.Qr

Efficient delivery of intensity-modulated proton therapy (IMPT) plays a pivotal role in improving the effectiveness of proton therapy. Accelerating delivery not only increases patient throughput but also improves the ability to manage dynamic target motion and reduces uncertainties, thereby enhancing treatment accuracy. Additionally, rapid delivery enables the effective use of breath-hold techniques, allowing for smaller target margins and providing better protection for healthy tissues. Since energy layer switching time constitute the majority of delivery time, reducing the number of energy layers can be highly beneficial for improving delivery efficiency. This work proposes a novel energy layer reduction method for rapid IMPT using a ridge filter. The width of the Bragg peak (BP) is extended using a ridge filter, referred to as the extended Bragg peak (EBP). The machine file of the generated EBP is subsequently incorporated in our in-house treatment planning system for inverse planning. The extended peak width reduces the number of energy layers required for target coverage. However, relying solely on EBP can compromise the accuracy of energy modulation. To address this limitation, pristine BP is utilized to fill small gaps left by EBP and ensure rapid dose fall-off at the distal and proximal edges of the target. To optimize the selection of BP and EBP energies, the problem is formulated as a mathematical model incorporating a group sparsity constraint. The model is then solved by a variant of block orthogonal matching pursuit algorithm, which selects BP and EBP energies in a greedy manner. The combined use of BP and EBP, referred to as the BP-EBP, considerably reduced the number of energy layers required compared to conventional IMPT. For example, in an abdomen case, the BP-EBP method decreased the energy layers from 79 to 28 (11 for BP and 17 for EBP) while maintaining comparable plan quality. Similarly, in a lung case, it reduced the energy layers from 70 to 30 (9 for BP and 21 for EBP), achieving slightly better plan quality than the conventional approach. Moreover, the BP-EBP reduced delivery time by more than 50% in both cases compared to conventional IMPT. Furthermore, the feasibility of BP-EBP was experimentally demonstrated on the ProteusONE proton therapy system. A novel energy reduction method is proposed and experimentally demonstrated that leverages BP and EBP generated by a ridge filter that significantly decreases the number of energy levels required in IMPT, thereby enhancing delivery efficiency.

We developed a machine learning framework in order to establish the correlation between dose and activity distributions in proton therapy. A recurrent neural network was used to predict dose distribution in three dimensions based on the information of proton-induced positron emitters. Hounsfield Unit (HU) information from CT images and analytically derived stopping power (SP) information were incorporated as auxiliary inputs. Four different scenarios were investigated: Activity only, Activity + HU, Activity + SP and Activity + HU + SP. The performance was quantitatively studied in terms of mean absolute error (MAE) and mean relative error (MRE), under different signal-to-noise ratios (SNRs). In addition to the first dataset of mono-energetic beams, three additional datasets were validated to help evaluate the generalization capability of our proposed model: a dataset of a lower SNR, five reconstructed PET images, and a dataset of spread-out Bragg peaks. Good verification accuracy of dose verification in three dimensions is demonstrated. The inclusion of anatomical information improves both accuracy and generalization. For an activity profile with an SNR of 4 (the mono-energetic case), the framework is able to obtain an MRE of ∼ 0.99% over the whole range and a range uncertainty of ∼ 0.27 mm. The machine learning-based framework may emerge as a useful tool to allow for online dose verification and quality assurance in proton therapy.

PurposeEye‐dedicated proton therapy (PT) facilities are used to treat malignant intraocular lesions, especially uveal melanoma (UM). The first commercial ocular PT beamline from Varian was installed in the Netherlands. In this work, the conceptual design of the new eyeline is presented. In addition, a comprehensive comparison against five PT centers with dedicated ocular beamlines is performed, and the clinical impact of the identified differences is analyzed.Material/MethodsThe HollandPTC eyeline was characterized. Four centers in Europe and one in the United States joined the study. All centers use a cyclotron for proton beam generation and an eye‐dedicated nozzle. Differences among the chosen ocular beamlines were in the design of the nozzle, nominal energy, and energy spectrum. The following parameters were collected for all centers: technical characteristics and a set of distal, proximal, and lateral region measurements. The measurements were performed with detectors available in‐house at each institution. The institutions followed the International Atomic Energy Agency (IAEA) Technical Report Series (TRS)‐398 Code of Practice for absolute dose measurement, and the IAEA TRS‐398 Code of Practice, its modified version or International Commission on Radiation Units and Measurements Report No. 78 for spread‐out Bragg peak normalization. Energy spreads of the pristine Bragg peaks were obtained with Monte Carlo simulations using Geant4. Seven tumor‐specific case scenarios were simulated to evaluate the clinical impact among centers: small, medium, and large UM, located either anteriorly, at the equator, or posteriorly within the eye. Differences in the depth dose distributions were calculated.ResultsA pristine Bragg peak of HollandPTC eyeline corresponded to the constant energy of 75 MeV (maximal range 3.97 g/cm2 in water) with an energy spread of 1.10 MeV. The pristine Bragg peaks for the five participating centers varied from 62.50 to 104.50 MeV with an energy spread variation between 0.10 and 0.70 MeV. Differences in the average distal fall‐offs and lateral penumbrae (LPs) (over the complete set of clinically available beam modulations) among all centers were up to 0.25 g/cm2, and 0.80 mm, respectively. Average distal fall‐offs of the HollandPTC eyeline were 0.20 g/cm2, and LPs were between 1.50 and 2.15 mm from proximal to distal regions, respectively. Treatment time, around 60 s, was comparable among all centers. The virtual source‐to‐axis distance of 120 cm at HollandPTC was shorter than for the five participating centers (range: 165–350 cm). Simulated depth dose distributions demonstrated the impact of the different beamline characteristics among institutions. The largest difference was observed for a small UM located at the posterior pole, where a proximal dose between two extreme centers was up to 20%.ConclusionsHollandPTC eyeline specifications are in accordance with five other ocular PT beamlines. Similar clinical concepts can be applied to expect the same high local tumor control. Dosimetrical properties among the six institutions induce most likely differences in ocular radiation‐related toxicities. This interinstitutional comparison could support further research on ocular post‐PT complications. Finally, the findings reported in this study could be used to define dosimetrical guidelines for ocular PT to unify the concepts among institutions.

Purpose:To demonstrate and evaluate the potential of optically stimulated luminescence (OSL) detectors (OSLDs) for measurements of linear energy transfer (LET) in therapeutic proton beams.Methods:Batches of Al2O2:C OSLDs were irradiated with an absorbed dose of 0.2 Gy in un‐modulated proton beams of varying LET (0.67 keV/μm to 2.58 keV/μm). The OSLDs were read using continuous wave (CW‐OSL) and pulsed (P‐OSL) stimulation modes. We parameterized and calibrated three characteristics of the OSL signals as functions of LET: CW‐OSL curve shape, P‐OSL curve shape and the ratio of the two OSL emission band intensities (ultraviolet/blue ratio). Calibration curves were created for each of these characteristics to describe their behaviors as functions of LET. The true LET values were determined using a validated Monte Carlo model of the proton therapy nozzle used to irradiate the OSLDs. We then irradiated batches of OSLDs with an absorbed dose of 0.2 Gy at various depths in two modulated proton beams (140 MeV, 4 cm wide spread‐out Bragg peak (SOBP) and 250 MeV, 10 cm wide SOBP). The LET values were calculated using the OSL response and the calibration curves. Finally, measured LET values were compared to the true values determined using Monte Carlo simulations.Results:The CW‐OSL curve shape, P‐OSL curve shape and the ultraviolet/blue‐ratio provided proton LET estimates within 12.4%, 5.7% and 30.9% of the true values, respectively.Conclusion:We have demonstrated that LET can be measured within 5.7% using Al2O3:C OSLDs in the therapeutic proton beams used in this investigation. From a single OSLD readout, it is possible to measure both the absorbed dose and LET. This has potential future applications in proton therapy quality assurance, particularly for treatment plans based on optimization of LET distributions.This research was partially supported by the Natural Sciences and Engineering Research Council of Canada.